Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week ...
Fintel on MSN3d
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM)
Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from ...
Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Overweight at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.
Nasdaq3d
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews
In the preceding three months, 4 analysts have released ratings for Beam Therapeutics (NASDAQ:BEAM), presenting a wide array of perspectives from bullish to bearish. The following table summarizes ...
Morningstar2d
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that ...
Nasdaq3d
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM)
Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...